Allogene Therapeutics Q1 Runway Extended, ALLO-501 Posts 65% Response Rate
Allogene Therapeutics reported Q1 2026 cash burn of $95M and $510M cash balance, extending runway into 2027, while its Phase 1 ALLO-501 trial achieved a 65% overall response rate in 34 relapsed/refractory lymphoma patients. Management outlined plans to initiate pivotal ALPHA-2 trial by Q3 2026.
1. Q1 2026 Financial Results
Allogene reported a cash burn of $95 million in Q1 and ended the quarter with $510 million in cash and equivalents, reflecting disciplined R&D expenditure. Revenue remained minimal as the company focuses on clinical development rather than commercial sales.
2. ALLO-501 Phase 1 Efficacy Data
In the Phase 1 study of ALLO-501 in relapsed/refractory lymphoma patients, 34 evaluable subjects achieved a 65% overall response rate, including a 40% complete response rate and manageable safety profile. These results support advancement to pivotal testing in a larger cohort.
3. Cash Runway and Financing
With $510 million on hand and quarterly burn of $95 million, the company’s cash runway extends into late 2027, reducing near-term financing needs. Management emphasized cost controls and potential non-dilutive funding opportunities to further bolster liquidity.
4. Upcoming Trials and R&D Plans
Allogene plans to launch the pivotal ALPHA-2 trial for ALLO-501 by Q3 2026, targeting accelerated enrollment in high-need lymphoma indications. Additional preclinical collaborations are under negotiation to expand its off-the-shelf cell therapy pipeline.